Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Here's Why Ignyta Stock Soared as Much as 27.5% Today


Here's Why Ignyta Stock Soared as Much as 27.5% Today

Shares of pre-revenue biopharma Ignyta (NASDAQ: RXDX) jumped over 27% Wednesday morning after it announced promising interim results from an ongoing phase 2/3 clinical trial investigating the potential of its lead drug candidate, entrectinib, to treat patients with a rare type of lung cancer.

Entrectinib demonstrated a 69% overall response rate in patients with the disease, and even demonstrated effectiveness in shrinking tumors in the brain, where the rare lung cancer often metastasizes. It was also well-tolerated, with mild side effects and only 3% of patients discontinuing treatment due to toxicity-related issues.  

As of 1:09 p.m. EDT, the stock had settled to a 12.1% gain.

Continue reading


Source: Fool.com

Pfizer Inc. Stock

€28.35
1.870%
Pfizer Inc. gained 1.870% today.
The stock is one of the favorites of our community with 28 Buy predictions and 4 Sell predictions.
As a result the target price of 41 € shows a positive potential of 44.65% compared to the current price of 28.35 € for Pfizer Inc..
Like: 0
PFE
Share

Comments